LOCO1 Flashcards
Pharmacological managementfor OA
COME BACK
- Start with oral analgesics &/ or topical NSAIDs
- Where paracetamol or topical NSAIDs are ineffective then substitute with oral NSAID/COX-2 inhibitor
- Intra-articular injections; Corticosteroid injections
State 6 surgical interventions for OA [6]
Arthroscopic lavage
Arthroscopic lavage plus debridement
Microfracture
Mosiacplasty (osteochondral transplant)
Chondrocyte grafts
Joint replacement
Explain the MoA of chondrocyte grafting
Take chondrocytes from other areas of the body (e.g. costochondral joint)
Grow chondrocytes in culture
Place in graft and get more hyaline cartilage
OA treatment
Explain MoA of mosaicplasty (osteochondral grafting) [1]
Take undamaged cartilage from less weight bearing regions plus the underlying bone and move to OA region
OA treatment
Adalimumab targets which cytokine? [1]
TNF inhibition
Gout is a disorder of metabolising which substance? [1]
What does this mean has deposition in soft tissue? [1]
Uric acid metabolism disordered: causes monosodium urate crystals get deposited in soft tissues
Describe the pathophysiology of gout
Sudden increase in the number of crystals and the body isn’t able to respond by coating crystals with serum proteins
Uncoated crystals in the joint that triggers an attack.
Naked urate crystals are then believed to interact with intracellular and surface receptors of local dendritic cells and macrophages, serving as a danger signal to activate the innate immune system
This interaction may be enhanced by immunoglobulin G (IgG) binding.
(Triggering of these receptors, including Toll-like receptors, NALP3 inflammasomes, and the triggering receptors expressed on myeloid cells (TREMs) by MSU) results in the production of interleukin (IL)–1, which in turn initiates the production of a cascade of pro-inflammatory cytokines, including IL-6, IL-8, neutrophil chemotactic factors, and tumour necrosis factor (TNF)–alpha
Neutrophil phagocytosis leads to another burst of inflammatory mediator production
Describe the role of neutrophils in gout pathogenesis
- Sudden increase in MSU uncoated crystals cause neutrophils to enter synovial fluid
- Neutrophils phagocytose MSU crystals, and macrophages that detect crystals release IL-1
- .The structure of MSU crystals cause neutrophil to be pierced, lyse and die
- Contents of neutrophil released: proteins, etc which bring more white blood cells in, and production of pro-inflammatory cytokines
- Acid released from neutrophils lowers pH, makes crystals precipitate even more: attack will start of pain, etc
- This inflammation from neutrophil phagocytosis is also aided by massive release of IL-1 from original macrophages that come into contact with crystal, which initiates a cascade of release of other cytokines like TNF-alpha, IL-6, IL-8, etc.
Explain the three mechanisms of gout development [3]
Purine overproduction:
* This occurs when there is increased cell turnover or lysis of cells leading to release of purines and breakdown to uric acid.
* Causes include myelo- or lymphoproliferative disorders, psoriasis and use of chemotherapy agents.
Increase purine intake:
* There are several foods and beverages that are rich in purines and increase the risk of developing gout.
* These include seafood (i.e. anchovies, sardines), red meat, alcohol and fructose-rich beverages.
Decreased uric acid secretion:
* Uric acid is predominantly renal excreted so anything that affects the kidneys can increase the risk of developing gout.
* Causes include diuretics (i.e. furosemide), acute kidney injury, chronic kidney disease, ACE inhibitors and diabetes mellitus
State two drug classes that could cause decreased uric acid secretion [2]
Name a disease that could cause high turnover of cells and therefore increased purine production [1]
Diuretics: Loop and Thiazide like
psoriasis
How would you treat acute gout / gout attack? [4]
NSAIDs:
* Start with highest dose for 2-3 days & taper down over 2 weeks
Colchicine:
* 2nd line (narrow therapeutic window and risk of toxicity)
Corticosteroids
* For those that can’t use NSAID or colchicine
IL1 biologicals
* Rilonacept, canakinumab, anakinra
* Reduces length of attack and reoccurrences
* Used for patients who have severe and frequent flares
Which IL1 biologicals can be used to treat acute gout? [3]
Rilonacept, canakinumab, anakinra
Describe how you treat chronic gout [5]
Allopurinol:
* Blocks xanthine oxidase, which is responsible from converting xanthine (which comes from purines in the diet) to urate
Febuxostat:
* non-purine selective inhibitor of xanthine oxidase
uricosuric:
* increases uric acid excretion
Probenecid:
* increases the secretion of uric acid
* fewer side effects than allopurinol.
Rasburicase:
* Catalyses conversion of uric acid to allantoin
Describe the pathogenesis of pseudogout [2]
Deposition of calcium pyrophosphate in and around joints onto the surface of the articular cartilage and the fibrocartilage:
- Release of calcium pyrophosphate crystals into the joint space
- followed by neutrophils, macrophages etc phagocytosing the crystals: cytokine release and inflammation.
- The crystals are not as shiny or sharp/needle like, meaning they don’t cause NETosis and the attack is much milder, with a slower onset.
This sign is suggestive of
Osteoarthritis
Gout
Pseudogout
Rheumatoid arthritis
Osteoporosis
Rheumatoid arthritis: Bakers cyst
Teriparatide is a treatment for
Osteoarthritis
Gout
Pseudogout
Rheumatoid arthritis
Osteoporosis
Osteoporosis
Teriparatide is a recombinant PTH:
PTH upregulates RANKL - signals osteoblast to differentiate when have low Ca2+: work indirectly on osteoclasts to boost bone making potential
Intermittent exposure to PTH activates osteoblasts more than osteoclasts
Recombinant PTH used to treat OP is called? [1]
Teriparatide
Name drug A used to treat osteoporosis [1]
Denosumab
Name drug A used to treat osteoporosis [1]
Teriparatide
Osteoporosis treatment
Describe the MoA of Teriparatide [2]
Teriparatide is a recombinant PTH:
- PTH upregulates RANKL - signals osteoblast to differentiate when have low Ca2+: work indirectly on osteoclasts to boost bone making potential
- Intermittent exposure to PTH activates osteoblasts more than osteoclasts
Osteoporosis treatment
Describe the MoA of Denosumab [2]
PTH normally inhibits OPG.
Denosumab is a an osteoprotegrin artificial antibody & acts as a monoclonal antibody to RANK:
Denosumab: human monoclonal antibody that inhibits RANKL and helps regulate turnover in healthy bone. Denosumab binds with high specificity and affinity to the cytokine RANKL, inhibiting its action; as a result, osteoclast recruitment, maturation and action are inhibited, and bone resorption slows
Descibe pathophysiology of Pagets disease [2]
Describe the three phases of Pagets disease [3]
(Theory) osteoclasts: may be infected with a virus that alters them AND genetics
Phases:
1. increased rate of bone resorption:
* large number of giant osteoclasts
2. Compensatory phase / proliferative:
* increased bone formation & accelerated depostion in disorganised manner
3. Burnt out phase: sclerotic:
* Hyper-vascular bone marrow; Bone hypercellularity may diminish leaving dense “Pagetic bone”
How do serum results for Ca, PO4, ALP, PTH and 1,25(OH)D2 present for osteomalacia? [1]
Explain each result
Low Ca
Low PO4
ALP high
PTH high
Vit D low
- Main cause of osteomalacia: low vitamin d
- Low PO4 and Ca due to phosphate being excreted in order to keep any calcium possible via renal regulation).
- ALP high because produced in osteoblasts
- PTH high due to low Ca2+
How do serum results for Ca, PO4, ALP, PTH and 1,25(OH)D2 present for Pagets disease? [5]
Explain your answer [1]
Ca: normal
PO4: normal
ALP: raised
PTH normal
Vit D: normal
ALP raised due to characterised by high burn turnover
How do serum results for Ca, PO4, ALP, PTH and 1,25(OH)D2 present for renal failure [5]
Explain your answer [1]
failure leads to vitamin D deficiency, as 1,25(OH)2 D3 is made in the kidney.
This results in high PO4, low calcium and normal/high alkaline phosphatase